Batu Biologics is an immunotherapy company dedicated to developing therapeutics that address the multi-factorial and multi-dimensional nature of cancer. Our company believes that a major failure of the conventional approach to oncology is attributed to the overspecialized focus on singular biological pathways, without understanding the “greater picture” of tumor biology. Cancer progression is a dynamic biologic process; tumors possess the ability to escape therapeutic interventions by mutating the targets of the intervention. In the case of chemotherapy, tumors develop resistance by mutating genes to make the cells less susceptible to chemotherapy. In the case of immune therapy, tumor cells lose expression of the protein markers (antigens) that the immune therapy is targeting. This can be seen by the recent failure of GSK’s Phase III cancer vaccine targeting a single tumor protein, MAGE.
Batu Biologics believes that the maximum efficacy of treating cancer can only be achieved by: a) targeting multiple tumor mechanisms concurrently; and b) targeting biological pathways that have already been demonstrated to be critical for the cancer to grow.
The Company has acquired intellectual property to develop parallel treatments for multiple pathways associated with tumor growth. Batu Biologics’ lead therapeutic product, ValloVax™, is a cancer vaccine targeting the tumor blood vessels – structures critical to sustainable tumor growth and progression to malignant stages.